
0:00
17:01
As the Bluestar team prepares to head to ASCO 2024 this upcoming weekend, Bluestar Principal Jeff Fineberg sits down with Bluestar Managing Director Erin Olsen to talk about interesting abstracts related to two topics:
- What are the unmet needs in 1L therapy?
- The KRAS G12C mutation landscape
More episodes from "Biotech Matters"



Don't miss an episode of “Biotech Matters” and subscribe to it in the GetPodcast app.






